



Surmodics to Participate in the Piper Sandler Healthcare Conference on November 28

November 14, 2023 at 4:05 PM EST

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Nov. 14, 2023-- Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that management will participate in the 35th Annual Piper Sandler Healthcare Conference, which is being held at the Lotte New York Palace in New York, NY from November 28-30, 2023. Management will present on Tuesday, November 28, at 8:30 a.m. ET (7:30 a.m. CT).

A live webcast of the presentation can be accessed by going to "Events & Presentations" under the "Investors" section of the company's website at <https://surmodics.gcs-web.com/events-and-presentations>, and clicking on the webcast icon under "Upcoming Events." A replay of the webcast will be archived on the website for the following 90 days.

About Surmodics, Inc.

Surmodics is a leading provider of performance coating technologies for intravascular medical devices and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays. Surmodics also develops and commercializes highly differentiated vascular intervention medical devices that are designed to address unmet clinical needs and engineered to the most demanding requirements. This key growth strategy leverages the combination of the Company's expertise in proprietary surface modification and drug-delivery coating technologies, along with its device design, development, and manufacturing capabilities. The Company's mission is to improve the detection and treatment of disease. Surmodics is headquartered in Eden Prairie, Minnesota. For more information, visit www.surmodics.com. The content of Surmodics' website is not part of this press release or part of any filings that the company makes with the Securities and Exchange Commission.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20231114314459/en/): <https://www.businesswire.com/news/home/20231114314459/en/>

Surmodics Investor Inquiries:
Jack Powell, Investor Relations
ir@surmodics.com

Source: Surmodics, Inc.